anonymous
Guest
anonymous
Guest
Hear you go, from the NYT:
“This place is a total joke. It's barely a pharmaceutical product. It's makes much more sens to buy over the counter fish oil for the same results. The company has one "product" and ZERO pipeline. Management is sitting around until 2018, hoping their study will lead to a buyout by a larger company. The fact that there a reps pushing fish oil is comical. If you're a Amarin DM, it's even more embarrassing. What a negative on the resume builder.”
“This place is a total joke. It's barely a pharmaceutical product. It's makes much more sens to buy over the counter fish oil for the same results. The company has one "product" and ZERO pipeline. Management is sitting around until 2018, hoping their study will lead to a buyout by a larger company. The fact that there a reps pushing fish oil is comical. If you're a Amarin DM, it's even more embarrassing. What a negative on the resume builder.”